Trilogy Capital’s Humacyte HUMA Stock Holding History

Trilogy Capital’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.83K	Hold	17,050	–	–	﹤0.01%	409
2026 Q2	$13.3K	Sell	17,050 -20,750	-55%	-$19.2K	﹤0.01%	403
2026 Q1	$22.9K	Sell	37,800 -17,000	-31%	-$17.7K	﹤0.01%	389
2025 Q4	$52.6K	Sell	54,800 -75,000	-58%	-$106K	﹤0.01%	382
2025 Q3	$226K	Hold	129,800	–	–	0.01%	360
2025 Q2	$271K	Sell	129,800 -40,000	-24%	-$76.8K	0.01%	305
2025 Q1	$290K	Buy	169,800 +86,300	+103%	+$324K	0.02%	286
2024 Q4	$422K	Buy	+83,500	New	+$413K	0.02%	244

Other funds holding HUMA

Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return

Miramontes Capital Newport, California $331M AUM 19.33% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Clarus Wealth Advisors Peoria, Arizona $275M AUM 18.32% 1-Year Est. Return

Lazari Capital Management Woodland Hills, California $339M AUM 25.58% 1-Year Est. Return

Columbia Advisory Partners Spokane, Washington $181M AUM 18.7% 1-Year Est. Return

Hamilton Lane Advisors Conshohocken, Pennsylvania $179M AUM 25.1% 1-Year Est. Return

Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.14% 1-Year Est. Return

Brookstone Capital Management Wheaton, Illinois $10.1B AUM 17.94% 1-Year Est. Return

Trilogy Capital's HUMA Position: Q3 2026 in Review

Trilogy Capital held its Humacyte (HUMA) position steady in Q3 2026 at 17,050 shares worth $8.83K. The position accounts for ﹤0.01% of the portfolio, ranked #409.

Trilogy Capital first reported a position in HUMA in Q4 2024 and has held it in 8 quarters since. The position peaked at $422K in Q4 2024. 24 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.

Trilogy Capital held 17,050 shares of Humacyte worth $8.83K as of Q3 2026.
Trilogy Capital left its Humacyte share count unchanged in Q3 2026.
Humacyte made up ﹤0.01% of Trilogy Capital's portfolio in Q3 2026, its #409 holding.
Trilogy Capital first reported a position in Humacyte in Q4 2024 and has held it in 8 quarters since.
Trilogy Capital's Humacyte position peaked at $422K in Q4 2024.
24 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.

Based on Trilogy Capital's 13F filing for Q3 2026, filed 20 Oct 2026.